Compare · MYO vs ZBH
MYO vs ZBH
Side-by-side comparison of Myomo Inc. (MYO) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYO and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $19.12B, about 326.2x MYO ($58.6M).
- MYO has been more active in the news (10 items in the past 4 weeks vs 7 for ZBH).
- ZBH has more recent analyst coverage (25 ratings vs 3 for MYO).
- Company
- Myomo Inc.
- Zimmer Biomet Holdings Inc.
- Price
- -
- -
- Market cap
- $58.6M
- $19.12B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2017
- News (4w)
- 10
- 7
- Recent ratings
- 3
- 25
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest MYO
- Amendment: Chief Medical Officer Kovelman Harry sold $30,329 worth of shares (17,500 units at $1.73), decreasing direct ownership by 14% to 105,733 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry sold $29,896 worth of shares (17,250 units at $1.73), decreasing direct ownership by 14% to 105,983 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 22,457 shares and was granted 55,149 shares, increasing direct ownership by 36% to 123,233 units (SEC Form 4)
- Chief Commercial Officer Mitchell Micah was granted 58,409 shares and covered exercise/tax liability with 21,559 shares, increasing direct ownership by 39% to 130,738 units (SEC Form 4)
- Chief Executive Officer Gudonis Paul R was granted 146,909 shares, increasing direct ownership by 11% to 1,434,679 units (SEC Form 4)
- Chief Financial Officer Henry David A was granted 68,644 shares and covered exercise/tax liability with 25,310 shares, increasing direct ownership by 10% to 470,163 units (SEC Form 4)
- SEC Form S-8 filed by Myomo Inc.
- SEC Form 10-Q filed by Myomo Inc.
- Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Myomo Reports Second Quarter 2026 Financial and Operating Results
Latest ZBH
- Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by President, APAC Desai Chintan
- SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zimmer Biomet Announces Second Quarter 2026 Financial Results
- Grp Pres-Global Business Thornal Kevin R converted options into 9,957 shares and covered exercise/tax liability with 4,266 shares (SEC Form 4) (tax liability)
- UBS initiated coverage on Zimmer Biomet with a new price target
- SEC Form 3 filed by new insider Desai Chintan
- Zimmer Biomet Names Chintan Desai President of Asia Pacific Region